Literature DB >> 33137689

Immune system control of hepatitis C virus infection.

Johnasha D Stuart1, Eduardo Salinas1, Arash Grakoui2.   

Abstract

Hepatitis C virus (HCV) remains a global public health problem even though more than 95% of infections can be cured by treatment with direct-acting antiviral agents. Resolution of viremia post antiviral therapy does not lead to protective immunity and therefore reinfections can occur. Immune cell detection of HCV activates signaling pathways that produce interferons and trigger the innate immune response against the virus, preventing HCV replication and spread. Cells in the innate immune system, including natural killer, dendritic, and Kupffer cells, interact with infected hepatocytes and present viral antigens to T and B cells where their effector responses contribute to infection outcome. Despite the immune activation, HCV can evade the host response and establish persistent infection. Plans to understand the correlates of protection and strategies to activate proper innate and adaptive immune responses are needed for development of an effective prophylactic vaccine that stimulates protective immunity and limits HCV transmission.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33137689      PMCID: PMC7979439          DOI: 10.1016/j.coviro.2020.10.002

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  78 in total

Review 1.  The role of Kupffer cells in hepatic diseases.

Authors:  Peizhi Li; Kun He; Jinzheng Li; Zuojin Liu; Jianping Gong
Journal:  Mol Immunol       Date:  2017-03-15       Impact factor: 4.407

2.  Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.

Authors:  Sachiyo Yoshio; Tatsuya Kanto; Shoko Kuroda; Tokuhiro Matsubara; Koyo Higashitani; Naruyasu Kakita; Hisashi Ishida; Naoki Hiramatsu; Hiroaki Nagano; Masaya Sugiyama; Kazumoto Murata; Takasuke Fukuhara; Yoshiharu Matsuura; Norio Hayashi; Masashi Mizokami; Tetsuo Takehara
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

3.  Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.

Authors:  M A Burchill; L Golden-Mason; M Wind-Rotolo; H R Rosen
Journal:  J Viral Hepat       Date:  2015-10-07       Impact factor: 3.728

4.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Authors:  Leo Swadling; Stefania Capone; Richard D Antrobus; Anthony Brown; Rachel Richardson; Evan W Newell; John Halliday; Christabel Kelly; Dan Bowen; Joannah Fergusson; Ayako Kurioka; Virginia Ammendola; Mariarosaria Del Sorbo; Fabiana Grazioli; Maria Luisa Esposito; Loredana Siani; Cinzia Traboni; Adrian Hill; Stefano Colloca; Mark Davis; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Paul Klenerman; Eleanor Barnes
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

5.  Natural Killer Cells in Viral Hepatitis.

Authors:  Barbara Rehermann
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-11

Review 6.  Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection.

Authors:  Mun-Teng Wong; Steve S-L Chen
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

7.  Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.

Authors:  Bogna Świątek-Kościelna; Ewelina Kałużna; Ewa Strauss; Jerzy Nowak; Iwona Bereszyńska; Ewelina Gowin; Jacek Wysocki; Jolanta Rembowska; Dominika Barcińska; Iwona Mozer-Lisewska; Danuta Januszkiewicz-Lewandowska
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

8.  Relationship of genetic polymorphisms in CTLA-4 and IL-18 with viral hepatitis: evidence from a meta-analysis.

Authors:  Yang Yu; Jie Qu; Chen Zhou; Guangqiang You
Journal:  Epidemiol Infect       Date:  2019-12-05       Impact factor: 2.451

9.  Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.

Authors:  Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

Review 10.  Hepatitis C Vaccines, Antibodies, and T Cells.

Authors:  Naglaa H Shoukry
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

View more
  5 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 2.  Drug combination therapy for emerging viral diseases.

Authors:  Zeenat A Shyr; Yu-Shan Cheng; Donald C Lo; Wei Zheng
Journal:  Drug Discov Today       Date:  2021-05-21       Impact factor: 7.851

Review 3.  The Role of B Cells in Adult and Paediatric Liver Injury.

Authors:  Arzoo M Patel; Yuxin S Liu; Scott P Davies; Rachel M Brown; Deirdre A Kelly; Dagmar Scheel-Toellner; Gary M Reynolds; Zania Stamataki
Journal:  Front Immunol       Date:  2021-09-23       Impact factor: 8.786

4.  HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels.

Authors:  Maria Rendina; Ernesto Paoletti; Nunzia Labarile; Antonella Marra; Andrea Iannone; Antonino Castellaneta; Elisabetta Bussalino; Maura Ravera; Antonio Schena; Nicola M Castellaneta; Michele Barone; Simona Simone; Loreto Gesualdo; Alfredo Di Leo
Journal:  Ther Adv Chronic Dis       Date:  2022-09-17       Impact factor: 4.970

Review 5.  Viral hepatitis update: Progress and perspectives.

Authors:  María B Pisano; Cecilia G Giadans; Diego M Flichman; Viviana E Ré; María V Preciado; Pamela Valva
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.